Literature DB >> 32214841

ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients.

Hyun Jeong Kim1, Nga Thi Trinh1, Yunjeong Choi1, Woorim Kim1, Kyung Hyun Min1, Sang Oh Kang1, Joo Hee Kim2, Hyoun-Ah Kim3, Ju-Yang Jung3, In Ah Choi4, Kyung Eun Lee1.   

Abstract

PURPOSE: TNF-α is a transmembrane protein which requires cleavage by ADAM17 in order to act systemically. The activation of ADAM17 to generate soluble TNF‑α results in an increased inflammatory activity. We hypothesized that variants spanning the ADAM17 gene contribute towards the observed variation in patient response defined by the number of changes in TNF‑α inhibitors. PATIENTS AND METHODS: Seven single-nucleotide polymorphisms (SNPs) of ADAM17 in 63 patients with rheumatoid arthritis who received TNF-α inhibitors were analyzed: rs57467365, rs62117540, rs117645314, rs6432013, rs532704607, rs117179141, and rs12692386. Univariate and multivariate regression analysis were employed to investigate the independent predictable factors for changes in TNF-α inhibitors.
RESULTS: ADAM17 rs117645314 and rs117179141 showed significant association with the number of changes in TNF-α inhibitors. Patients with GA in rs117645314 and AT in rs117179141 had significantly higher chance of two or more changes of TNF-α inhibitors than those with wild homozygous alleles. Multivariate analysis showed that rs117179141 explained 5.7% of the 23.8% variability in TNF-α inhibitor response.
CONCLUSION: This study showed that the number of changes in TNF-α inhibitor is associated with ADAM17 SNPs.
© 2020 Kim et al.

Entities:  

Keywords:  ADAM17; TNF-α inhibitor; rheumatoid arthritis; single-nucleotide polymorphism

Year:  2020        PMID: 32214841      PMCID: PMC7083627          DOI: 10.2147/PGPM.S235035

Source DB:  PubMed          Journal:  Pharmgenomics Pers Med        ISSN: 1178-7066


  29 in total

1.  The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.

Authors:  M Seitz; U Wirthmüller; B Möller; P M Villiger
Journal:  Rheumatology (Oxford)       Date:  2006-05-23       Impact factor: 7.580

2.  Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  K L Hyrich; K D Watson; A J Silman; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2006-05-16       Impact factor: 7.580

Review 3.  The role of ADAM17 in metabolic inflammation.

Authors:  Rossella Menghini; Loredana Fiorentino; Viviana Casagrande; Renato Lauro; Massimo Federici
Journal:  Atherosclerosis       Date:  2013-01-25       Impact factor: 5.162

Review 4.  Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.

Authors:  Stephan Pavy; Erik J M Toonen; Corinne Miceli-Richard; Pilar Barrera; Piet L C M van Riel; Lindsey A Criswell; Xavier Mariette; Marieke J H Coenen
Journal:  Ann Rheum Dis       Date:  2009-12-04       Impact factor: 19.103

Review 5.  ADAM17 at the interface between inflammation and autoimmunity.

Authors:  Sabrina Lisi; Massimo D'Amore; Margherita Sisto
Journal:  Immunol Lett       Date:  2014-08-27       Impact factor: 3.685

Review 6.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

Review 7.  Single nucleotide polymorphisms and cancer susceptibility.

Authors:  Na Deng; Heng Zhou; Hua Fan; Yuan Yuan
Journal:  Oncotarget       Date:  2017-11-07

8.  Transmembrane TNF-dependent uptake of anti-TNF antibodies.

Authors:  Arun Deora; Subramanya Hegde; Jacqueline Lee; Chee-Ho Choi; Qing Chang; Cheryl Lee; Lucia Eaton; Hua Tang; Dongdong Wang; David Lee; Mark Michalak; Medha Tomlinson; Qingfeng Tao; Nidhi Gaur; Bohdan Harvey; Shaun McLoughlin; Boris Labkovsky; Tariq Ghayur
Journal:  MAbs       Date:  2017-03-21       Impact factor: 5.857

Review 9.  Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.

Authors:  S Bek; A B Bojesen; J V Nielsen; J Sode; S Bank; U Vogel; V Andersen
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

10.  Ensembl variation resources.

Authors:  Sarah E Hunt; William McLaren; Laurent Gil; Anja Thormann; Helen Schuilenburg; Dan Sheppard; Andrew Parton; Irina M Armean; Stephen J Trevanion; Paul Flicek; Fiona Cunningham
Journal:  Database (Oxford)       Date:  2018-01-01       Impact factor: 3.451

View more
  2 in total

Review 1.  ADAM17, A Key Player of Cardiac Inflammation and Fibrosis in Heart Failure Development During Chronic Catecholamine Stress.

Authors:  Joseph Adu-Amankwaah; Gabriel Komla Adzika; Adebayo Oluwafemi Adekunle; Marie Louise Ndzie Noah; Richard Mprah; Aisha Bushi; Nazma Akhter; Fei Huang; Yaxin Xu; Seyram Yao Adzraku; Iqra Nadeem; Hong Sun
Journal:  Front Cell Dev Biol       Date:  2021-12-13

2.  Genetic polymorphism of ADAM17 and decreased bilirubin levels are associated with allergic march in the Korean population.

Authors:  Jaemee Jung; Dahyun Hwang
Journal:  BMC Med Genomics       Date:  2022-02-07       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.